Evidence map›Paper›PMID 24314911›Full record

ArticleContraception2014

Effect of lubricants and a vaginal spermicide gel on the detection of prostate specific antigen, a biomarker of semen exposure, using a quantitative (Abbott ARCHITECT) assay.

Margaret C Snead, Johan H Melendez, Athena P Kourtis, Dorothy M Chaney, Teresa M Brown, Carolyn M Black, Christine K Mauck, Jill L Schwartz, Jonathan M Zenilman, Denise J Jamieson and 2 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Contraception, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Trial
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 1 country.

Margaret C SneadDivision of Reproductive Health, National Center for Chronic Disease Prevention and Health Promotion, and the Division of Scientific Resources, National Center for Emerging and Ζoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30341, USA. Electronic address: msnead@cdc.gov.
Johan H MelendezJohns Hopkins University, Department of Infectious Diseases, Baltimore, MD 21224, USA.
Athena P KourtisDivision of Reproductive Health, National Center for Chronic Disease Prevention and Health Promotion, and the Division of Scientific Resources, National Center for Emerging and Ζoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30341, USA.
Dorothy M ChaneyJohns Hopkins University, Department of Infectious Diseases, Baltimore, MD 21224, USA.
Teresa M BrownDivision of Reproductive Health, National Center for Chronic Disease Prevention and Health Promotion, and the Division of Scientific Resources, National Center for Emerging and Ζoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30341, USA.
Carolyn M BlackDivision of Reproductive Health, National Center for Chronic Disease Prevention and Health Promotion, and the Division of Scientific Resources, National Center for Emerging and Ζoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30341, USA.
Christine K MauckCONRAD, Eastern Virginia Medical School (EVMS), Arlington, VA 23501, USA.
Jill L SchwartzCONRAD, Eastern Virginia Medical School (EVMS), Arlington, VA 23501, USA.
Jonathan M ZenilmanJohns Hopkins University, Department of Infectious Diseases, Baltimore, MD 21224, USA.
Denise J JamiesonDivision of Reproductive Health, National Center for Chronic Disease Prevention and Health Promotion, and the Division of Scientific Resources, National Center for Emerging and Ζoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30341, USA.
Maurizio MacalusoDivision of Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA.
Gustavo F DoncelCONRAD, Eastern Virginia Medical School (EVMS), Arlington, VA 23501, USA.
Johns Hopkins University · USCenters for Disease Control and Prevention · USContraception Research and Development · USNational Center for Chronic Disease Prevention and Health Promotion · USCincinnati Children's Hospital Medical Center · USEastern Virginia Medical School · USNational Center for Emerging and Zoonotic Infectious Diseases · US

Funding

Intramural CDC HHS CC999999
6 · The paper itself

Abstract

objectivesLittle is known about the effects of commonly used lubricants on detection of biomarkers of semen exposure. We investigated the in vitro effect of Gynol®, K-Y Jelly®, Replens®, Astroglide®, Carbopol, and Silicorel on quantitative detection of prostate specific antigen (PSA). STUDY

designA predetermined concentration of each of the gels was added to serially diluted semen samples. Additionally, serial dilutions of each of the gels were added to three different semen dilutions (high, medium, or low). The resulting samples were tested for PSA on the Abbott ARCHITECT System.

resultsWhen using the Abbott ARCHITECT system, the only products that inhibited PSA detection were Gynol® and Replens®. The inhibition caused by Gynol® was dose-dependent, but that of Replens was dose-independent. K-Y Jelly®-spiked samples had higher PSA values than controls.

conclusionsCaution is warranted when using the Abbott quantitative assay for PSA detection as a biomarker of semen exposure in settings where Gynol®, Replens® or K-Y Jelly® might also have been used. Neither Astroglide® nor Silicorel inhibited PSA detection. Additional studies evaluating other vaginal products, including microbicides, and their effects on other assays, are needed. In vivo studies will be especially important to optimize PSA detection from clinical samples. IMPLICATIONS: Researchers should consider the potential for specific lubricants or any vaginal products to affect the particular assay used for semen biomarker detection. The Abbott ARCHITECT's total PSA assay should not be used with the product Replens. Caution is warranted when using the assay in settings where Gynol or K-Y jelly may have been used.

Indexed as

LubricantsSpermatocidal AgentsContraindicationsFemaleHumansImmunoassayLuminescent MeasurementsMaleProstate-Specific AntigenLubricantsProstate-Specific AntigenSpermatocidal AgentsLubricantsProstate-specific antigenSemen biomarkersSpermicideVaginal products

Identifiers

PMID24314911
PMCPMC4554523
OpenAlexW2045152754

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.